Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Clinical trial NCT05992584 · UNKNOWN

Trial details

NCT number: NCT05992584
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2023-08-10
Primary completion: 2026-01-09
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.